White House Reviews 340B Rebate Proposal
The White House has completed its initial regulatory review of a new 340B rebate proposal from the Department of Health and Human Services. The policy, focused on prescription drug pricing, will likely impact EHR data capture and reporting workflows due to its emphasis on transparency. This highlights the growing intersection of federal policy, clinical documentation, and health IT system configuration.
- The 340B Drug Pricing Program was established by Congress in 1992 to allow certain healthcare providers, known as "covered entities," to purchase outpatient drugs from manufacturers at a significant discount, typically 20-50%. The program's stated intent is to permit these entities, which serve a large number of low-income patients, to "stretch scarce federal resources." - Participation in the program has grown dramatically, from about 8,100 provider sites in 2000 to over 50,000 in 2020. In 2023, discounted drug purchases under the 340B program reached an estimated $66.3 billion. - A central point of conflict involves "contract pharmacies," where covered entities contract with external pharmacies to dispense 340B-discounted drugs. Several drug manufacturers have sought to limit these arrangements, arguing they lack oversight and lead to duplicate discounts, while hospitals contend these networks are crucial for patient access. - The proposed rebate model would shift the program from an upfront discount at the time of purchase to a post-sale rebate paid by the manufacturer to the hospital. Hospitals argue this would create a significant financial burden, forcing them to float millions in costs while waiting for reimbursement. - The Health Resources and Services Administration (HRSA), an agency within HHS, is responsible for administering the 340B program. However, its authority to enforce program rules has been the subject of numerous legal challenges from pharmaceutical manufacturers. - Critics of the program, including pharmaceutical manufacturers, argue there is a lack of transparency regarding how hospitals use the revenue generated from 340B discounts. While hospitals state the savings are used to fund care for vulnerable populations, there is no legal requirement to directly pass the discounts on to patients or to report how the funds are used. - A key issue manufacturers cite is the risk of "duplicate discounts," where they might pay a rebate to state Medicaid programs on top of providing a 340B discount for the same drug. Preventing this is a statutory requirement, but the mechanisms for doing so are a source of ongoing dispute. - The financial stakes are substantial; one analysis estimated that large hospitals participating in the 340B program have commercial prices for outpatient procedures that are nearly 20% higher than non-340B hospitals. Conversely, safety-net hospitals report that restrictions on 340B savings could force them to reduce services or even close facilities.
